KCC-07

Research use only, not for human use.

KCC-07 is a selective, potent and brain-penetrant inhibitor of methyl-CpG-binding domain protein 2(MBD2) with anticancer activity.

KCC-07 is a selective, potent and brain-penetrant inhibitor of methyl-CpG-binding domain protein 2(MBD2) with anticancer activity. KCC-07 prevents binding of MBD2 to methylated DNA and activates brain specific angiogenesis inhibitor 1 (BAI1) inducing anti-proliferative BAI1/p53/p21 signaling. In vitro, KCC-07 treatment Medulloblastomas (MB) cells?clearly inhibited MB cell growth, consistent with induction of anti-proliferative BAI1/p53/p21 signaling.

Cell Viability Assay Cell Line:Medulloblastomas (MB) cells Concentration:10 μM Incubation Time:72 hours Result:Clearly inhibited MB cell growth in vitro.Western Blot Analysis Cell Line:Medulloblastomas (MB) cells Concentration:10 μM Incubation Time:48 hours Result:Largely abrogated MBD2 binding to the ADGRB1 promoter in BAI1-silent MB cells.

Animal Model:Outbred athymic nude mice (females; 8-10 weeks old) injected with MB cells Dosage:100 mg/kg Administration:Intraperitoneal injection; 5 days/week Result:Significantly extended the survival of MB xenografts in vivo.

——

Cell Cycle/DNA Damage

DNA Alkylator

MBD2 (methyl-CpG-binding domain protein 2)

——

——

315702-75-1

269.32

C14H11N3OS?

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (464.13 mM)

Oc1cccc(Nc2nc(cs2)-c2ccccn2)c1

——

(-20℃)

With Ice Pack

≥ 2 years